神州细胞：2025年预亏5.2亿元到5.8亿元

Core Viewpoint - Shenzhou Cell (688520.SH) is expected to report a significant net loss for the year 2025, with projected losses ranging from 520 million to 580 million yuan, primarily due to declining sales and increased commercialization costs [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between -580 million and -520 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be between -563 million and -503 million yuan [1] - Research and development expenditures for 2025 are expected to be between 830 million and 870 million yuan [1] Reasons for Performance Change - The decline in core product sales revenue, particularly for the product Anjia, due to ongoing healthcare cost control policies in the industry, has significantly impacted overall revenue [1] - Increased commercialization investments, including academic promotion and sales team formation, have led to a noticeable rise in sales expenses in the short term [1] - The company continues to pursue a multi-product pipeline strategy, with several projects entering critical confirmatory clinical trial phases, maintaining high levels of R&D investment, which has affected current profitability [1]